CD19-Directed CAR T-Cell Therapy Leads to Exceptionally Long Remissions in Some Patients with Relapsed or Refractory B-Cell non-Hodgkin Lymphomas By Ogkologos - July 16, 2026 93 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from 10-year follow-up of a phase II study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Rationale Explained for Granting EMA Authorisation for Extended Use of Nivolumab... November 18, 2020 EMA Recommends Granting a Marketing Authorisation for Ivosidenib March 1, 2023 Some Hormone Therapy Drugs For Breast Cancer Could Reduce Alzheimer’s Risk May 8, 2020 Patient Guide in Colorectal Cancer Now Available in Bulgarian February 18, 2026 Load more HOT NEWS Low Risk of Cardiotoxicity with Immune Checkpoint Inhibitor Monotherapy or Combination... 3…2…1…Countdown to Medicare Open Enrollment Significant Activity, Clinically Meaningful Functional and Symptomatic Improvements Observed in Patients... Genetic Mechanisms Identified for Acquired Resistance to Non-Covalent BTK Inhibitors
